Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 138

1.

Cognitive impairment and in vivo metabolites in first-episode neuroleptic-naive and chronic medicated schizophrenic patients: a proton magnetic resonance spectroscopy study.

Ohrmann P, Siegmund A, Suslow T, Pedersen A, Spitzberg K, Kersting A, Rothermundt M, Arolt V, Heindel W, Pfleiderer B.

J Psychiatr Res. 2007 Oct;41(8):625-34. Epub 2006 Sep 1.

PMID:
16949099
[PubMed - indexed for MEDLINE]
2.

N-acetyl-aspartate levels in the dorsolateral prefrontal cortex in the early years of schizophrenia are inversely related to disease duration.

Molina V, Sánchez J, Reig S, Sanz J, Benito C, Santamarta C, Pascau J, Sarramea F, Gispert JD, Misiego JM, Palomo T, Desco M.

Schizophr Res. 2005 Mar 1;73(2-3):209-19. Review.

PMID:
15653263
[PubMed - indexed for MEDLINE]
3.

[Cognition, schizophrenia and the effect of antipsychotics].

Stip E.

Encephale. 2006 May-Jun;32(3 Pt 1):341-50. Review. French.

PMID:
16840928
[PubMed - indexed for MEDLINE]
4.

Proton magnetic resonance spectroscopy of the human brain in schizophrenia.

Deicken RF, Johnson C, Pegues M.

Rev Neurosci. 2000;11(2-3):147-58. Review.

PMID:
10718151
[PubMed - indexed for MEDLINE]
5.

[Functional MRI in schizophrenia. Diagnostics and therapy monitoring of cognitive deficits of schizophrenic patients by functional MRI].

Furtner J, Prayer D, Sachs G.

Radiologe. 2010 Feb;50(2):131-5. doi: 10.1007/s00117-009-1895-y. Review. German.

PMID:
20076939
[PubMed - indexed for MEDLINE]
6.

Specific relationship between prefrontal neuronal N-acetylaspartate and activation of the working memory cortical network in schizophrenia.

Bertolino A, Esposito G, Callicott JH, Mattay VS, Van Horn JD, Frank JA, Berman KF, Weinberger DR.

Am J Psychiatry. 2000 Jan;157(1):26-33. Review.

PMID:
10618009
[PubMed - indexed for MEDLINE]
7.

What have we learned from proton magnetic resonance spectroscopy about schizophrenia? A critical update.

Abbott C, Bustillo J.

Curr Opin Psychiatry. 2006 Mar;19(2):135-9. Review.

PMID:
16612192
[PubMed - indexed for MEDLINE]
8.

[Hypofrontality and negative symptoms in schizophrenia: synthesis of anatomic and neuropsychological knowledge and ecological perspectives].

Semkovska M, Bédard MA, Stip E.

Encephale. 2001 Sep-Oct;27(5):405-15. Review. French.

PMID:
11760690
[PubMed - indexed for MEDLINE]
9.

Neurochemical investigation of the schizophrenic brain by in vivo phosphorus magnetic resonance spectroscopy.

Fukuzako H.

World J Biol Psychiatry. 2001 Apr;2(2):70-82. Review.

PMID:
12587188
[PubMed - indexed for MEDLINE]
10.

Organization of cognitive control within the lateral prefrontal cortex in schizophrenia.

Barbalat G, Chambon V, Franck N, Koechlin E, Farrer C.

Arch Gen Psychiatry. 2009 Apr;66(4):377-86. doi: 10.1001/archgenpsychiatry.2009.10. Review.

PMID:
19349307
[PubMed - indexed for MEDLINE]
11.

Familial and developmental abnormalities of front lobe function and neurochemistry in schizophrenia.

Deakin FW, Simpson MD, Slater P, Hellewell JS.

J Psychopharmacol. 1997;11(2):133-42. Review.

PMID:
9254279
[PubMed - indexed for MEDLINE]
12.

Neurochemical alterations of the brain in bipolar disorder and their implications for pathophysiology: a systematic review of the in vivo proton magnetic resonance spectroscopy findings.

Yildiz-Yesiloglu A, Ankerst DP.

Prog Neuropsychopharmacol Biol Psychiatry. 2006 Aug 30;30(6):969-95. Epub 2006 May 4. Review. Erratum in: Prog Neuropsychopharmacol Biol Psychiatry. 2007 Mar 30;31(2):591.

PMID:
16677749
[PubMed - indexed for MEDLINE]
13.

Proton magnetic resonance spectroscopy (H-MRS) studies of schizophrenia.

Rowland L, Bustillo JR, Lauriello J.

Semin Clin Neuropsychiatry. 2001 Apr;6(2):121-30. Review.

PMID:
11296312
[PubMed - indexed for MEDLINE]
14.

[Neurologic symptoms in schizophrenia].

Nuss P, Ferreri F, Agbokou C, Peretti CS.

Encephale. 2007 Jun;33 Pt 3:S392-4. doi: 10.1016/S0013-7006(07)74588-8. Review. French. No abstract available.

PMID:
19101357
[PubMed - indexed for MEDLINE]
15.

Relationship of prefrontal and temporal lobe MRI measures to neuropsychological performance in chronic schizophrenia.

Seidman LJ, Yurgelun-Todd D, Kremen WS, Woods BT, Goldstein JM, Faraone SV, Tsuang MT.

Biol Psychiatry. 1994 Feb 15;35(4):235-46. Review.

PMID:
8186328
[PubMed - indexed for MEDLINE]
16.

[Genetic and pharmacological effects on prefrontal cortical function in schizophrenia].

Heinz A, Braus DF, Romero B, Gallinat J, Puls I, Juckel G, Weinberger DR.

Nervenarzt. 2004 Sep;75(9):845-56. Review. German.

PMID:
15372159
[PubMed - indexed for MEDLINE]
17.

[Magnetic resonance spectroscopy in schizophrenia].

Delamillieure P, Constans JM, Fernandez J, Dollfus S.

Encephale. 2000 Jan-Feb;26(1):21-31. Review. French.

PMID:
10875059
[PubMed - indexed for MEDLINE]
18.

Measurement of brain metabolites by 1H magnetic resonance spectroscopy in patients with schizophrenia: a systematic review and meta-analysis.

Steen RG, Hamer RM, Lieberman JA.

Neuropsychopharmacology. 2005 Nov;30(11):1949-62. Review.

PMID:
16123764
[PubMed - indexed for MEDLINE]
Free Article
19.

1H MR spectroscopy in patients with mesial temporal epilepsy.

Hájek M, Dezortová M, Komárek V.

MAGMA. 1998 Dec;7(2):95-114. Review.

PMID:
9951770
[PubMed - indexed for MEDLINE]
20.

Magnetic resonance spectroscopy.

Duncan JS.

Epilepsia. 1996 Jul;37(7):598-605. Review.

PMID:
8681890
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk